Kambe Tohru, Maruyama Toru, Naganawa Atsushi, Asada Masaki, Seki Akiteru, Maruyama Takayuki, Nakai Hisao, Toda Masaaki
Minase Research Institute, Ono Pharmaceutical Co., Ltd., Mishima, Osaka 618–8585, Japan.
Chem Pharm Bull (Tokyo). 2011;59(12):1494-508. doi: 10.1248/cpb.59.1494.
For the purpose of discovering an orally available EP4 subtype-selective agonist, a series of 8-aza prostaglandin E(1) (PGE(1)) analogs were synthesized and evaluated for their affinity for PGE(2) receptor subtypes. Additionally, the structure-activity relationships of these compounds were studied. Among the tested compounds, the 8-aza PGE(1) analog 6 and 8-aza-5-thiaPGE(1) analog 12 had highly potent EP4 receptor affinity, good functional activity, and excellent subtype-selectivity. Furthermore, these analogs demonstrated good stability in human liver microsomes. As a result, we concluded that these two series of 8-aza PGE(1) analogs could be promising chemical leads for an orally available EP4 subtype-selective agonist.
为了发现一种口服可用的EP4亚型选择性激动剂,合成了一系列8-氮杂前列腺素E(1)(PGE(1))类似物,并评估了它们对PGE(2)受体亚型的亲和力。此外,还研究了这些化合物的构效关系。在测试的化合物中,8-氮杂PGE(1)类似物6和8-氮杂-5-硫杂PGE(1)类似物12具有高效的EP4受体亲和力、良好的功能活性和出色的亚型选择性。此外,这些类似物在人肝微粒体中表现出良好的稳定性。因此,我们得出结论,这两个系列的8-氮杂PGE(1)类似物可能是口服可用的EP4亚型选择性激动剂的有前景的化学先导物。